Literature DB >> 21536658

Oncogenic tyrosine kinases target Dok-1 for ubiquitin-mediated proteasomal degradation to promote cell transformation.

Justyna A Janas1, Linda Van Aelst.   

Abstract

Cellular transformation induced by oncogenic tyrosine kinases is a multistep process involving activation of growth-promoting signaling pathways and inactivation of suppressor molecules. Dok-1 is an adaptor protein that acts as a negative regulator of tyrosine kinase-initiated signaling and opposes oncogenic tyrosine kinase-mediated cell transformation. Findings that its loss facilitates transformation induced by oncogenic tyrosine kinases suggest that Dok-1 inactivation could constitute an intermediate step in oncogenesis driven by these oncoproteins. However, whether Dok-1 is subject to regulation by oncogenic tyrosine kinases remained unknown. In this study, we show that oncogenic tyrosine kinases, including p210(bcr-abl) and oncogenic forms of Src, downregulate Dok-1 by targeting it for degradation through the ubiquitin-proteasome pathway. This process is dependent on the tyrosine kinase activity of the oncoproteins and is mediated primarily by lysine-dependent polyubiquitination of Dok-1. Importantly, restoration of Dok-1 levels strongly suppresses transformation of cells expressing oncogenic tyrosine kinases, and this suppression is more pronounced in the context of a Dok-1 mutant that is largely refractory to oncogenic tyrosine kinase-induced degradation. Our findings suggest that proteasome-mediated downregulation of Dok-1 is a key mechanism by which oncogenic tyrosine kinases overcome the inhibitory effect of Dok-1 on cellular transformation and tumor progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21536658      PMCID: PMC3133381          DOI: 10.1128/MCB.05045-11

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  99 in total

Review 1.  Defective downregulation of receptor tyrosine kinases in cancer.

Authors:  Kristi G Bache; Thomas Slagsvold; Harald Stenmark
Journal:  EMBO J       Date:  2004-07-01       Impact factor: 11.598

2.  Molecular basis of distinct interactions between Dok1 PTB domain and tyrosine-phosphorylated EGF receptor.

Authors:  Yong Zhang; Zhiyong Yan; Amjad Farooq; Xiujie Liu; Changlin Lu; Ming-Ming Zhou; Cheng He
Journal:  J Mol Biol       Date:  2004-10-29       Impact factor: 5.469

3.  Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases.

Authors:  C Ellis; M Moran; F McCormick; T Pawson
Journal:  Nature       Date:  1990-01-25       Impact factor: 49.962

4.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

Authors:  T G Lugo; A M Pendergast; A J Muller; O N Witte
Journal:  Science       Date:  1990-03-02       Impact factor: 47.728

5.  Protein-tyrosine kinases regulate the phosphorylation, protein interactions, subcellular distribution, and activity of p21ras GTPase-activating protein.

Authors:  M F Moran; P Polakis; F McCormick; T Pawson; C Ellis
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

6.  Mast cell growth factor (c-kit ligand) enhances cytokine stimulation of proliferation of the human factor-dependent cell line, M07e.

Authors:  P C Hendrie; K Miyazawa; Y C Yang; C D Langefeld; H E Broxmeyer
Journal:  Exp Hematol       Date:  1991-11       Impact factor: 3.084

7.  Activation of c-Src in cells bearing v-Crk and its suppression by Csk.

Authors:  H Sabe; M Okada; H Nakagawa; H Hanafusa
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

8.  Dok-6, a Novel p62 Dok family member, promotes Ret-mediated neurite outgrowth.

Authors:  Robert J Crowder; Hideki Enomoto; Mao Yang; Eugene M Johnson; Jeffrey Milbrandt
Journal:  J Biol Chem       Date:  2004-07-30       Impact factor: 5.157

9.  Dok-1 tyrosine residues at 336 and 340 are essential for the negative regulation of Ras-Erk signalling, but dispensable for rasGAP-binding.

Authors:  Hisaaki Shinohara; Tomoharu Yasuda; Yuji Yamanashi
Journal:  Genes Cells       Date:  2004-06       Impact factor: 1.891

10.  Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo.

Authors:  R Palacios; M Steinmetz
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

View more
  12 in total

1.  Docking protein-1 promotes inflammatory macrophage signaling in gastric cancer.

Authors:  Tong Li; Beifang Li; Asgharpour Sara; Christine Ay; Wing Yan Leung; Yanquan Zhang; Yujuan Dong; Qiaoyi Liang; Xiang Zhang; Philip Weidner; Tobias Gutting; Hans-Michael Behrens; Christoph Röcken; Joseph Jy Sung; Matthias P Ebert; Jun Yu; Elke Burgermeister
Journal:  Oncoimmunology       Date:  2019-08-21       Impact factor: 8.110

2.  Nudel is crucial for the WAVE complex assembly in vivo by selectively promoting subcomplex stability and formation through direct interactions.

Authors:  Shuang Wu; Li Ma; Yibo Wu; Rong Zeng; Xueliang Zhu
Journal:  Cell Res       Date:  2012-03-27       Impact factor: 25.617

3.  A method for systematic mapping of protein lysine methylation identifies functions for HP1β in DNA damage response.

Authors:  Huadong Liu; Marek Galka; Eiichiro Mori; Xuguang Liu; Yu-Fen Lin; Ran Wei; Paula Pittock; Courtney Voss; Gurpreet Dhami; Xing Li; Masaaki Miyaji; Gilles Lajoie; Benjamin Chen; Shawn Shun-Cheng Li
Journal:  Mol Cell       Date:  2013-05-23       Impact factor: 17.970

4.  DOK3 negatively regulates LPS responses and endotoxin tolerance.

Authors:  Qisheng Peng; Jason L O'Loughlin; Mary Beth Humphrey
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

5.  Genetic disruption of the sh3pxd2a gene reveals an essential role in mouse development and the existence of a novel isoform of tks5.

Authors:  Pilar Cejudo-Martin; Angela Yuen; Nicole Vlahovich; Peter Lock; Sara A Courtneidge; Begoña Díaz
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

6.  BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration.

Authors:  Sayem Miah; Raghuveera Kumar Goel; Chenlu Dai; Natasha Kalra; Erika Beaton-Brown; Edward T Bagu; Keith Bonham; Kiven E Lukong
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

Review 7.  Nilotinib for the Frontline Treatment of Chronic Myeloid Leukemia Carrying the p230 Transcript: Dream or Reality?

Authors:  Maurizio Capuozzo; Alessandro Ottaiano; Eduardo Nava; Stefania Cascone; Claudia Cinque; Adriano Vercellone; Corinne Scognamiglio; Emilia Palumbo; Rosario V Iaffaioli
Journal:  Front Oncol       Date:  2014-02-03       Impact factor: 6.244

8.  Epstein-Barr virus down-regulates tumor suppressor DOK1 expression.

Authors:  Maha Siouda; Cecilia Frecha; Rosita Accardi; Jiping Yue; Cyrille Cuenin; Henri Gruffat; Evelyne Manet; Zdenko Herceg; Bakary S Sylla; Massimo Tommasino
Journal:  PLoS Pathog       Date:  2014-05-08       Impact factor: 6.823

9.  Oncogene-mediated regulation of p53 ISGylation and functions.

Authors:  Yi-Fu Huang; Dmitry V Bulavin
Journal:  Oncotarget       Date:  2014-07-30

Review 10.  The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase.

Authors:  Sabrina Crivellaro; Giovanna Carrà; Cristina Panuzzo; Riccardo Taulli; Angelo Guerrasio; Giuseppe Saglio; Alessandro Morotti
Journal:  BMC Cancer       Date:  2016-05-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.